Current Topics - UK Pharmacy Services

August 31, 2005 (Volume 35 Number 8)
	Cardiology - useful websites Website - cardiology Tigecycline - formulary addition with restrictions Nystatin/topical powder - therapeutic substitution Miconazole topical powder - therapeutic substitution Nalbuphine - formulary addition Isotretinoin - formulary deletion Fenofibrate - automatic dosage conversion
August 22, 2005 (Volume 35 Number 7)
	Promethazine - safety alert in pediatrics Nesiritide - safety alert
August 2005 (Volume 35 Number 6)
	Atypical Antipsychotics - safety in the elderly Insulin - comparison chart Fenofibrate - automatic therapeutic interchange Nystatin powder - automatic therapeutic interchange Miconazole powder - automatic therapeutic interchange Tolterodine, extended release - formulary addition Tegaserod - formulary addition
July 2005 (Volume 35 Number 5)
	Digoxin Immune Antigen - Binding Fragments (Fab) - appropriate use Digoxin Toxicity - treatment Digibind� - appropriate use DigiFab� - appropriate use Reminyl� - renamed Razadyne� Razadyne� - new name
June 2005 (Volume 35 Number 4)
	Meropenem - new pharmacodynamic dosing strategy Beers' criteria - safe medication use in the elderly Medication safety - safe use in the elderly (Beers' criteria) Medication safety - colchicine dosage and administration Colchicine - safe dosage and administration Inspra� - look-alike, sound-alike error with Spiriva� Spiriva� - look-alike, sound-alike error with Inspra� Eplerenone - look-alike, sound-alike error with tiotropium Tiotropium - look-alike, sound-alike error with epleronone Acamprosate - formulary addition Campath� - formulary addition Bupropion XL - formulary addition Wellbutrin XL� - formulary addition Duloxetine - formulary addition Cymbalta� - formulary addition
March 2005 (Volume 35 Number 3)
	Clostridium difficile infection - risk and treatment Antibiotics - risk of Clostridium difficile infection Meperidine - automatic stop date Demerol� - automatic stop date Meperidine - restrictions for use Zyprexa� - look-alike, sound-alike error with Zyrtec� Zyrtec� - look-alike, sound-alike error with Zyprexa� Cisatracurium - restrictions for use Atracurium - formulary deletion Isradipine - formulary addition
February 2005 (Volume 35 Number 2)
	Levofloxacin - short-course therapy for CAP Community-Acquired Pneumonia - short-course levofloxacin therapy Propofol - infusion syndrome Metformin - look-alike, sound-alike with metronidazole Metronidazole - look-alike, sound-alike with metformin Current Topics newsletter - conversion to electronic distribution
January 2005 (Volume 35 Number 1)
	Pulmonary embolism - thrombolytic therapy Alteplase - use in pulmonary embolism Spironolactone - hyperkalemia Hyperkalemia - spironolactone Spironolactone - congestive heart failure Papain/Urea/Chlorophyllin Copper Complex Sodium - formulary addition Panafil� - formulary addition Niacin extended release (Niaspan�) - formulary addition Niaspan� - formulary addition Papain/Urea (Accuzyme�) - formulary deletion Accuzyme� - formulary deletion Niacin immediate release - formulary deletion Niacin sustained action - formulary deletion Kaopectate� - reformulation Tissue Plasminogen Activator (recombinant) - use in pulmonary embolism
December 2004 (Volume 34 Number 10)
	FDA Safety Alerts 2004 Medicaid requirements for CMN/DME Moxifloxacin ophthalmic solution - formulary addition Levofloxacin ophthalmic solution - formulary addition Omeprazole capsules and suspension - formulary deletion Paregoric solution - formulary deletion Ciprofloxacin ophthalmic solution - formulary deletion Ocufloxacin ophthalmic solution - formulary deletion Chromagen capsule - formulary deletion Trimethobenzamide - formulary deletion Propoxyphene napsylate tablet - formulary deletion Bretylium injection - formulary deletion Prochlorperazine oral syrup - formulary deletion Levalbuterol inhalation - restrictions revised Pemetrexed injection - restrictions revised Lansoprazole capsules and suspension - formulary addition with restrictions Rasburicase injection - formulary addition with restrictions
November 2004 (Volume 34 Number 9)
	Vaccination Evaluation Program Pneumococcal Vaccination Program Darbepoetin Conversion Epoetin to Darbepoetin Conversion
October 2004 (Volume 34 Number 8)
	Rofecoxib - formulary deletion, withdrawal from the market Urinary Tract Infection Guidelines - compliance with University of Kentucky Guide to Empiric Antimicrobial Therapy
September 2004 (Volume 34 Number 7)
	Antihistamines - therapeutic interchange for second generation agents Loratadine - formulary addition Loratadine - therapeutic interchange Fexofenadine - formulary removal Fexofenadine - therapeutic interchange Cetirizine - therapeutic interchange Desloratadine - therapeutic interchange Grapefruit juice - drug interactions Medicaid - pharmacy program update (antipsychotics) Enoxaparin - renal dosing guidelines Nifedipine capsules - use for acute lowering of blood pressure Midodrine - formulary addition Azacitadine - formulary addition with restrictions Thyrotropin alfa - formulary addition with restrictions
June/July 2004 (Volume 34 Number 6)
	AMT website AMT - 2004 Guide to Empiric Antimicrobial Therapy Published Pharmacy Services Orientation Drug Information Center Orientation Formulary Orientation Tiotropium (Spiriva�) - formulary addition Sildenafil (Viagra�) - formulary addition with restrictions Ibuprofen Lysine Injection (investigational use) - formulary addition with restrictions Pamidronate (Aredia�) - formulary deletion Bicarbonate-based dialysis solution (Normocarb�) - formulary deletion
May 2004 (Volume 34 Number 5)
	Perioperative antimicrobial prophylaxis - adult and pediatric guidelines Cefazolin - perioperative antimicrobial prophylaxis Clindamycin - perioperative antimicrobial prophylaxis Metronidazole - perioperative antimicrobial prophylaxis Ampicillin - perioperative antimicrobial prophylaxis Ampicillin/sulbactam - perioperative antimicrobial prophylaxis Sulfamethoxazole/trimethoprim - perioperative antimicrobial prophylaxis Gentamicin - perioperative antimicrobial prophylaxis Doxycycline - perioperative antimicrobial prophylaxis Vancomycin - perioperative antimicrobial prophylaxis Medicaid (Kentucky) - June 2004 pharmacy program changes Imatinib mesylate - formulary deletion Bevacizumab - formulary addition and restrictions for use Cetuximab - formulary addition and restrictions for use Capecitabine - removal of restrictions for use Ondansetron - revised restrictions for use Oxaliplatin - revised restrictions for use
April 2004 (Volume 34 Number 4)
	Fenoldopam - CONTRAST trial Fenoldopam - revised restrictions for use Atazanavir - formulary addition Prismasate� - formulary addition Carbamazepine extended release capsules - formulary addition Carbatrol� - formulary addition Voriconazole - revised restrictions for use Contrast-induced nephropathy - CONTRAST trial
March 2004 (Volume 34 Number 3)
	Bumetanide - guidelines for continuous infusion Contrast-induced nephropathy - guidelines for prevention Hydration - guidelines for prevention of contrast-induced nephropathy N-acetycystine - guidelines for prevention of contrast-induced nephropathy Acetylcystine - guidelines for prevention of contrast-induced nephropathy Wellbutrin� - risk for medication error Bupropion - risk for medication error Cyclosporine ophthalmic emulsion - formulary addition Entacapone - formulary addition Eplerenone - formulary addition Pramipexole - formulary addition Ropinirole - formulary addition Talc, sterile - formulary addition Sterile talc - formulary addition Bortezommib - formulary addition, restrictions Mepivicaine - formulary addition, restrictions Pemetrexed - formulary addition, restrictions Albumin 5% - restrictions removed Amphotericin B Lipid Complex - revision of restriction Divalproex sodium extended release - restrictions removed Depakote ER� - restrictions removed Fenoldopam - revision of restrictions Voriconazole - revision of restriction
February 2004 (Volume 34 Number 2)
	Zanamivir - drug therapy for influenza infection Oseltamivir - drug therapy for influenza infection Amantadine - drug therapy for influenza infection Rimantidine - drug therapy for influenza infection Influenza infection - drug therapy Levetiracetam liquid - formulary addition
January 2004 (Volume 34 Number 1)
	Anticoagulation Management Service Anticoagulation Guidelines Warfarin - dosing guidelines Heparin - dosing guidelines Warfarin - factors altering pharmacokinetics and pharmacodynamics Vitamin K - guideline for administration INR - optimal therapeutic range for oral anticoagulation Abbreviations - update to list of banned abbreviations Ela-Max� - name change LMX4� - name change Procaine 2% injection - formulary deletion

December 2003 (Volume 33, Number 11)
	Safety alerts - medical product safety alerts 2003 Dactinomycin - potential medication error with daptomycin Daptomycin - potential medication error with dactinomycin Sterile water for injection - clarification of medication error

October/November 2003 (Volume 33, Number 10)
	Sterile Water for Injection - Potential for medication Influenza vaccination Linezolid - drug interaction with SSRI's SSRI's - drug interaction with linezolid Medication range order interpretation Fenofibrate - formulary addition Daptomycin - formulary addition with restrictions Bivalirudin - formulary addition with restrictions Factor VIIa - formulary addition with restrictions Thiethylperazine - formulary deletion Ipecac syrup - formulary deletion

September 2003 (Volume 33, Number 8)
	Corticosteroids - insufficiency in the acutely ill Vincristine - error potential with intrathecal administration Ramipril - formulary addition Quinapril - formulry addition

August 2003 (Volume 33, Number 7)
	Iodine - allergy and drug precautions Extravasation - management Epoprostenol - standardization of preparation and administration Flolan� - standardization of preparation and administration Eletriptan - formulary addition Zolmitriptan -formulary deletion

July 2003 (Volume 33, Number 6)
	Abbreviations - banned drug abbreviations Adverse drug - reporting process Pharmacokinetic service Pharmacy - phone directory - services: description - overview, phone numbers, hours Drug Information Center - description Drug policy overview MicroMedex Outpatient Pharmacy Services Phone Numbers - website Formulary system description Therapeutic interchange - policy Restricted drugs - policy Antimicrobial Management Team Restricted Antimicrobial Order Form Darbepoetin - formulary addition Aprepitant - restrictions for use Emend - restrictions for use Cytarabine, liposomal - formulary denial DepoCyt - formulary denial

June 2003 (Volume 33, Number 5)
	Glucocorticoid, Injectable - Shortage, Alternatives for Use Contrast Media Drug Interactions Medication Error: Liquid-Filled Capsules Formulary Update

May 2003 (Volume 33, Number 4)
	Zonisamide - New Warning for Oligohydrosis and Hyperthermia in Pediatric Patients Enoxaparin - Preferred Low Molecular Weight Heparin Heparins - Updated Dosing Guidelines ELISA for Heparin/PF4 Antibody-Test Available

April 2003 (Volume 33, Number 3)
	Aripiprazole (Abilify�) - Addition to Formulary Ezetimibe (Zetia�) - Addition to Formulary Diphtheria, Tetanus, Acellular Pertussis (DTaP), Hepatitis B, and Injectable Polio Vaccine Combination (Pediarix�) - Addition to Formulary Capecitabine (Xeloda�) - Addition to Formulary With Restriction Atomoxetine (Strattera�) - Addition to Formulary With Restriction EMLA� - Formulary Deletion Lidocaine/Prilocaine (EMLA�) - Formulary Deletion Heparin-Induced Thrombocytopenia Guidelines Thrombocytopenia - Drug-Induced

March 2003 (Volume 33, Number 2)
	Tramadol - Addition to Formulary Zonisamide - Addition to Formulary Ziprasidone Injection - Addition to Formulary With Restrictions Fulvestrant - Addition to Formulary with Restrictions Pegfilgrastim - Addition to Formulary with Restrictions Pravastatin - Restrictions for Use Removed Leuprolide - Addition of Restrictions for Use Saliva Monitoring of Antiepileptics Venous Thromboembolism in Pregnancy Pregnancy - Venous Thromboembolism Kaopectate� - reformulation

January/February 2003 (Volume 33, Number 1)
	Abbreviations - Banned Drug Abbreviations ACD-A� - Addition to Formulary with Restrictions AMT - Website Launched Bicarbonate-Based Dialysis Solution - Addition to Formulary with Restrictions BNP - Correction to Protocol Calfactant - Restrictions for Use Revised Escitalopram - Addition to Formulary Flumazenil - Restrictions for Use Revised Levocarnitine - Addition to Formulary Senna/docusate - Addition to Formulary Sodium benzoate - Addition to Formulary Somatropin - Restrictions for Use Revised Valsartan - Addition to Formulary Vancomycin - Revised Monitoring Voriconazole - Drug Interactions

November 2002 (Volume 32, Number 10)
	Influenza Vaccination - 2002 Recommendations IV to Oral - Antimicrobial Conversion Program Fluconazole - IV to PO Conversion Levofloxacin - IV to PO Conversion Linezolid - IV to PO Conversion

October 2002 (Volume 32, Number 9)
	Vitamin K - Guidelines for Use Phytonadione - Guidelines for Use Valdecoxib - New Warnings of Allergic Reactions Lepirudin - Labeling Changes for Adverse Reactions - Labeling Changes for Conversion to Oral Anticoagulation Methotrexate - Medication Error Gelclair� - Addition to Formulary Valacyclovir - Deletion From Formulary Oxaloplatin - Addition to Formulary With Restrictions Ramipril - Not Added to Formulary Valdecoxib - Not Added to Formulary

September 2002 (Volume 32, Number 8)
	Pioglitazone - Fluid Retention Ziprasidone - Drug Interactions, QT Prolongation Sibutramine - Request for Withdrawal From Market Grapefruit Juice - Drug Interactions Morphine Solution - Medication Error Cefdinir - Restrictions Removed Ticarcillin/Clavulanate - Restrictions for Use Liposomal Amphotericin B - Formulary Status, Not to Be Dispensed

August 2002 (Volume 32, Number 7)
	Vasopressin Injection - Uses and Dosing RAOF - Restricted Antimicrobial Order Form Zyvox - Risk for Error Zovirax - Risk for Error Tenofovir - Formulary Addition Combivir - Formulary Addition Trizivir - Formulary Addition Ropivicaine - Change in Restrictions Valganciclovir - Change in Restrictions Indinivir - Restriction Removal Ritonavir - Restriction Removal Saquinavir - Restriction Removal Cidofovir - Formulary Addition; Restrictions Diastat - Restrictions Voriconazole - Formulary Addition; Restrictions Itraconazole IV - Formulary Addition; Restrictions Imatinib - Formulary Addition; Restrictions

July 2002 (Volume 32, Number 6)
	BNP Assay - Heart Failure Nesiritide Protocol Micromedex - Website Pharmacokinetic Drug Monitoring Process Outpatient Pharmacy Services Phone Numbers - Website Adverse Drug Reactions - Online Reporting Formulary System Description Therapeutic Interchange - Policy Restricted Drugs - Policy Drug Shortage - Website

June 2002 (Volume 32, Number 5)
	New Drug Approvals - Safety Antimicrobial Resistance - CDC Recommendations Poison Control - Nationwide Toll-Free Number Trade Names - Risk of Overdose St. John's Wort - Drug Interaction With Irinotecan Metformin - Lactic Acidosis

May 2002 (Volume 32, Number 4)
	Transition to Oral Antimicrobial to Facilitate Hospital Discharge Nimodipine Administration Warning/Policy Pediatric Prescribing Policy Reminder Safety Issues With Enoxaparin Heparin Recalled, Potential for Error Exists Formulary Update

March/April 2002 (Volume 32, Number 3)
	Report Adverse Drug Events Online Interchange for HMG CoA Reductase Inhibitors New Warnings, Monitoring for Alpha Interferons Rofecoxib Associated With Aseptic Meningitis Immune Globulin Results in Thrombosis AIDS Drug, Lactic Acidosis Herbal Products Contain Prescription Compounds Formulary Update

February 2002 (Volume 32, Number 2)
	Policy Bans Dangerous Abbreviations Restricted Antimicrobial Order Form Developed Medication Safety Update Rally Pack Use in Alcoholics Supplemental Corticosteroid Therapy ECG Required With Droperidol Dolasetron Packaging Improved Drug Shortage Update Anthrax Vaccine Approved Formulary Update

January 2002 (Volume 32, Number 1)
	Just Say No to 'U' Drug Names Look Alike - A Real Case Children's Hospital Potassium Policy Hepatic Failure With Nefazodone Accutane� - SMART Program Set to Begin Lantus� - (Insulin Glargine) Humalog� - Mix 75/25 Formulary Update

November/December 2001 (Volume 31, Number 11)
	Drotrecogin Alfa Added to Formulary With Restrictions for Use Product Safety Update Current Topics Index for Volume 31 Formulary Update

October 2001 (Volume 31, Number 10)
	Amphotericin B To Now Be Infused Continuously Thalidomide - Monitoring Systems Can Be Effective Online ADR Reporting Approaches Topiramate Associated With Ocular Damage Hepatic Damage From Weight Loss Product Formulary Update

September 2001 (Volume 31, Number 9)
	Adult Proton Pump Inhibitor Therapeutic Interchange Updated Dietary Supplement May Induce Renal Failure Discontinuing Herbal Products Prior to Surgery Formulary Update

August 2001 (Volume 31, Number 8)
	OxyContin Warnings, Label Changes Another Influenza Vaccine Shortage? Augmentin Conversion Drug Shortage Update Medication Safety: Lantus vs. Lente Drug Names Look, Sound Alike (Part II) Cerivastatin Withdrawn No Formulary Changes Since the Last Issue

July 2001 (Volume 31, Number 7)
	Adult ICU Anemia Management Protocol Approved Dolasetron in PACU Pyxis for PONV Management Pediatric Prescribing Policy Implemented New Potassium Policy for Children's Hospital Welcome to the University of Kentucky - Drug Information Center - MicroMedex - Pharmacokinetic Drug Monitoring - Clinical and Distributive Services - Outpatient Pharmacy Services - The Formulary - Criteria-Based Drugs - Restricted Drugs - Therapeutic Interchange - Adverse Drug Reaction Reporting - Important Phone Numbers, Service Descriptions New Strategy for Non-IV PCAs Formulary Update

June 2001 (Volume 31, Number 6)
	Cox II Inhibitors and Renal Dysfunction: The Latest Findings Taxol� & Taxotere�: Associated Medication Errors Drug Names Look, Sound Alike Problems with Dolasetron Ampules Pharmacy 'Co-Pay' Therapy Available No Formulary Changes Since the Last Issue

May 2001 (Volume 31, Number 5)
	FDA Objects to Celebrex� Claims Pharmacy Services Website Debuts New Antipsychotic May Prolong QT Intervals Safety Concerns With Antifingals CDC Recommends Tetatnus Booster Delay Formulary Update

April 2001 (Volume 31, Number 4)
	Levofloxacin Becomes Sole Formulary Fluoroquinolone for Adult Patients Applicability of UHC Albumin Guidelines in Pediatrics Rapacuronium Withdrawn From Market Adjust Famotidine Dosage in Moderate Renal Failure IV Dexamethasone Shortage No Formulary Changes Since the Last Issue

March 2001 (Volume 31, Number 3)
	Linezolid and Myelosuppression Topical Miconazole Increases INR Recent Drug Withdrawals, Restrictions and Safety Labeling Changes Formulary Update

February 2001 (Volume 31, Number 2)
	Proton Pump Inhibitor (PPI) Formulary Change and Therapeutic Interchange Drugs That May Affect the QT Interval News From the FDA - Isotretinoin, Rivastigmine Formulary Update

January 2001 (Volume 31, Number 1)
	Albumin Use to Be Examined UHC Guidelines for Use of Albumin, Nonprotein Colloids and Crystalloid Solutions Osteltamivir Use Restricted Formulary Update

November/December 2000 (Volume 30, Number 11)
	Phenylpropanolamine Market Withdrawal New ACLS Guidelines Formulary Changes in Inhaled Corticosteroids Drug Interactions With Grapefruit Juice Lepirudin Use Restricted Alosetron Removed From Market Capecitabine and Renal Dysfunction Safety Issues With Etanercept Volume 30 Index Formulary Update

October 2000 (Volume 30, Number 10)
	ucg or mcg? Medication Error Alert FDA Issues Important Safety Information Amiodarone Interactions, Part II Medication Use in Sulfa Allergy

September 2000 (Volume 30, Number 9)
	LMWHs Available for DVT Treatment Influenza Vaccine Delayed Minimizing the Impact of Interactions With Amiodarone Medications to Avoid in Patients With a Sulfa Allergy Formulary Update

August 2000 (Volume 30, Number 8)
	Once-daily Aminoglycosides Valproate Pancreatitis Warnings Strengthened Antiretroviral Metabolic Syndrome Reported Thioridazine Joins QTc Prolongation List Formulary Update

July 2000 (Volume 30, Number 7)
	Therapeutic Interchange for Low Molecular Weight Heparins Pharmacokinetic Monitoring Welcome to the University of Kentucky Drug Information Center MicroMedex Pharmacokinetic Drug Monitoring Clinical and Distributive Services Outpatient Pharmacy Services The Formulary Criteria-Based Drugs Restricted Drugs Therapeutic Interchange Adverse Drug Reaction Reporting Important Phone Numbers, Service Descriptions

June 2000 (Volume 30, Number 6)
	Smoking Cessation Program Nutraceutical Policy Medication Samples Policy Rofecoxib and Myocardial Infarction Doxazosin Discontinued From ALLHAT Clopidogrel and TTP Amrinone Becomes Inamrinone Trastuzumab Infusion-Related Reactions COX-2 Inhibitor Restrictions and Prescribing Guidelines Dalteparin Added to Formulary Formulary Update

May 2000 (Volume 30, Number 5)
	Adult Colony Stimulating Factor Guidelines Approved Rezulin Withdrawn From Market, Cisapride to Follow MicroMedex Available for Use Neutropenic Fever Guidelines Clarified Formulary Update

April 2000 (Volume 30, Number 4)
	Therapeutic Interchange for Proton Pump Inhibitors Percocet Prescribing Dilemma ... The Answer is Roxicet Sulfonylurea Dosage Conversion Recommendations Anusol Therapeutic Interchange U vs. Units: Avoiding Medication Errors Potential Safety Concerns With Herbs and Natural Products Formulary Update

March 2000 (Volume 30, Number 3)
	Neutropenic Fever Practice Guidelines Approved Formulary Update

February 2000 (Volume 30, Number 2)
	Dietary Supplements are Drugs, Too Latest Warnings for Cisapride Released Fomepizole Added to Formulary, Guidelines Created Therapeutic Interchange Implemented for HMG-CoA Reductase Inhibitors Formulary Update

January 2000 (Volume 30, Number 1)
	ICU Analgesic/Sedation Guidelines Created Calcium Channel Blocker Therapeutic Interchange Formulary Update

December 1999 (Volume 29, Number 11)
	Criteria for COX-2 Inhibitors Approved Highlights of Formulary Changes Current Topics 1999 Index (Volume 29) Formulary Update

November 1999 (Volume 29, Number 10)
	Several Formulary Changes Recently Made Role of Digibind Outlined Adult Guidelines for Electrolyte Infusions Children's Hospital Potassium Guidelines Formulary Update

October 1999 (Volume 29, Number 9)
	Famotidine Therapeutic Interchange and IV to PO Conversion Influenza Vaccination Recommendations Ketorolac Not to Exceed Five Days Renal Failure Warning With Immune Globulin

September 1999 (Volume 29, Number 8)
	Guidelines for Prevention of Chemotherapy-Induced Emesis Implemented Formulary Update

August 1999 (Volume 29, Number 7)
	Zolpidem and Tramadol No Longer Available Gene Therapy Under Way in Kentucky Reacting to High INR Values: Recommendations From ACCP Formulary Update